linjc16/ctgov huggingface dataset:
EPAD Monitoring of Patients Undergoing Robotic Assisted Laparoscopic Genitourinary Surgery

Study Overview
=================
Brief Summary
-----------------
Participants to be enrolled in this study will have been scheduled to have laparoscopic genitourinary surgery and EPAD monitoring as part of their clinical care intraoperatively. Patients scheduled for genitourinary surgery are often at risk for developing nerve injuries due to intraoperative positioning. Somatosensory evoked potential devices (SSEP) are commonly used to detect pending injury to peripheral nerves. The purpose of the present study is to use SSEP monitoring to determine the incidence and potential causes of significant changes in SSEP waveforms and correlate these changes with neurologic status of the brachial plexus after robotic surgery.

Official Title
-----------------
EPAD Monitoring of Patients Undergoing Robotic Assisted Laparoscopic Genitourinary Surgery

Conditions
-----------------
Surgery

Intervention / Treatment
-----------------
* Device: EPAD monitoring system


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients scheduled to undergo robotic assisted laparoscopic genitourinary surgery Patients who are scheduled to have EPAD monitoring as part of their clinical care intraoperatively Exclusion Criteria: • Patients with previous history of polyneuropathy, carpal tunnel, ulnar neuropathy, or similar neurological deficiencies

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Observation<br>All participants will be monitored with EPAD system | Device: EPAD monitoring system<br>* EPAD system will be used as part of routine care<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Somatosensory Evoked Potential Monitoring | Recording of somatosensory evoked potential in patients undergoing genitourinary surgery | in the first 24 hours of postoperative period |
Near Normalisation of BG Improves the Potentiating Effect of GLP-1

Study Overview
=================
Brief Summary
-----------------
The ability of glucagon-like peptide 1 to enhance beta-cell responsiveness to I.v. glucose is impaired in patients with type 2 diabetes mellitus compared with healthy individuals. We investigated whether 4 weeks of near-normalisation og blood glucose improves the potentiation of glucose-stimulated insulin secretion by GLP-1

Official Title
-----------------
Near Normalisation of Blood Glucose Improves the Potentiating Effect of GLP-1 on Glucose Induced Insulin Secretion in Patients With Type 2 Diabetes

Conditions
-----------------
Diabetes Mellitus Type 2

Intervention / Treatment
-----------------
* Drug: glucagon-like peptide-1
* Drug: Saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-70 years Type 2 diabetes diagnosed after 30 years of age BMI > 25 Exclusion Criteria: Severe complications to diabetes Abnormal liver og kidney function Haemoglobin below the lower limit Macroalbuminuria Systemic disease Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: GLP-1<br>A graded glucose infusion with an infusion of GLP-1 (1½ pmol/kg/min) | Drug: glucagon-like peptide-1<br>* continuous infusion of GLP-1 (1½ pmol/kg/min)<br>|
| Experimental: Saline<br>A graded glucose infusion together with a continuous infusion of saline | Drug: Saline<br>* continuous infusion of saline<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| insulin secretion rate (ISR) were derived by deconvolution of c-peptide. ISR is expressed as pmol/kg/min |  | 180 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The calculated ISR values was plotted against the ambient plasma glucose. The slopes of this linear relationships were calculated by cross-correlation analysis and is and estimation of beta-cell responsiveness (pmol/kg/min)/mmol/l |  | 180 minutes |
Laser - a New Possibility in Fertility Treatment - a Pilot Study

Study Overview
=================
Brief Summary
-----------------
In this study the investigators want to investigate if the pregnancy rate in conjunction with fertility treatment increases with concomitant use of laser therapy.

Detailed Description
-----------------
Furthermore the investigators want to examine the participants general mental and physical wellbeing during the experimental period using a VAS-scale.

Official Title
-----------------
Laser - a New Possibility in Fertility Treatment - a Pilot Study

Conditions
-----------------
Infertility, Exposure Laser

Intervention / Treatment
-----------------
* Device: + laser


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI : 18-32 long agonist/short antagonist IVF/intracytoplasmatic sperm injection (ICSI)treatment 1-2 IVF/ICSI treatments without obtaining pregnancy. signed consent Exclusion Criteria: uterine malformations Uterine fibroids/polyps need of an interpreter. D.M, epilepsy, liver-kidney-heart disease endometrial biopsy cancer former cancer disease acupuncture metal in the body suspicious naevi and tatoo´s

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention (+ laser)<br>+ laser therapy | Device: + laser<br>* Use of laser in the treatment<br>|
| Placebo Comparator: Non-intervention (- laser)<br>- laser | Device: + laser<br>* Use of laser in the treatment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical pregnancy rate |  | up to24 months |
Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency

Study Overview
=================
Brief Summary
-----------------
This clinical trial is designed to provide additional information on the safety and tolerability of vildagliptin (50 mg once daily (qd)) when used in patients with type 2 diabetes mellitus (T2DM) and moderate or severe renal insufficiency.

Official Title
-----------------
A Multi-center, Randomized, Double-blind Clinical Trial to Evaluate the Safety and Tolerability of 24 Weeks Treatment With (50 mg qd) Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency

Conditions
-----------------
Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Drug: Vildagliptin
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: History T2DM Moderate or Severe Renal Impairment Exclusion Criteria: Glucose > 270 mg/dL (>15 mmol/L) Other protocol-defined inclusion/exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: Vildagliptin<br> <br> * Other names: Galvus;|
| Placebo Comparator: 2<br> | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the safety and tolerability in patients with T2DM and moderate or severe renal insufficiency over 24 weeks of treatment |  | 24 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess concentration levels of vildagliptin and its metabolites in patients with T2DM and moderate or severe renal insufficiency. |  | 24 weeks | 
| To explore the efficacy of vildagliptin (50 mg qd) versus placebo in patients with T2DM and moderate or severe renal insufficiency. |  | 24 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Type 2 diabetes, vildagliptin
Comparison Between Foresee Home and Optical Coherence Tomography (OCT) Visual Field Defects in Patients With Choroidal Neovascularization (CNV)

Study Overview
=================
Brief Summary
-----------------
The Foresee Home is used in the recent years to detect age-related macular degeneration (AMD) lesions. The device is capable of differentiation as to stages of AMD and early detection of changes including choroidal neovascularization (CNV). The Foresee Home demonstrates a high level of sensitivity and specificity as to the different stages of AMD including newly diagnosed or early detection of CNV. The OCT may be use as well to identify choroidal neovascularization (CNV). Comparison between the two methods will allow better understanding of both devices. The Foresee Home can use as an assessment tool for the progression and success of the treatment given to AMD lesions. Therefore, evaluation the size and the location of the treated lesions may serve as an additional tool.

Official Title
-----------------
Comparison Between Home Macular Perimeter (FORESEE HOME) and OCT Visual Field Defects in Patients With CNV

Conditions
-----------------
Age Related Macular Degeneration

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Capable and willing to sign a consent form and participate in the study Subjects diagnosed with CNV Did not perform more then 4 anti- VGEF injections VA with habitual correction better then 6/45 in the study eye Ability to understand instructions Familiar with computer usage Exclusion Criteria: Evidence of macular disease other than AMD or glaucoma in the study eye Presence of any significant media opacity that precludes a clear view of the macular area as identified in the study eye by biomicroscopy, Any non-macular related ocular surgery performed within 3 months prior to study entry in the target eye Participation in another study with the exclusion of AREDS study

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CNV patiens<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Size and location of lesions |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HMP, CNV, AMD, PHP, HPHP, FORESEE HOME
Lower Limb Muscle Activity With BOBO

Study Overview
=================
Brief Summary
-----------------
Balance disorders are sometimes treated with exercises performed on unbalanced surfaces. The BOBO system allows connection of a standing platform attached to any of these surfaces, to a screen, where the user can control games with his or her body movements. In this study, the lower limb muscle activity of healthy individuals will be monitored during different games in order to assert the the ability of each game in strengthening certain muscle groups.

Detailed Description
-----------------
Healthy subject will fill out a demographic questionnaire following the exercise they will fill out a subjective questionnaire for assessment of the exercise. Each subject will play 4 games using the BOBO while surface electrodes are placed on the gluteus max/medius, quadriceps, hamstring, peroneal ,tibialis anterior, gastrocnemius.

Official Title
-----------------
Lower Limb Muscle Activity During Task-specific Exercises With BOBO

Conditions
-----------------
Healthy Volunteers

Intervention / Treatment
-----------------
* Device: BOBO


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Native Hebrew speaking Exclusion Criteria: Familiar with the BOBO system Previous lower limb injuries Have a pacemaker Have neurological or vestibular deficiencies

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: BOBO<br>Playing with the BOBO system. | Device: BOBO<br>* Each subject will play four games with the BOBO system.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measuring the muscle activity using an Electromyography device | The muscle activities of lower limb muscles using surface Electromyography device will be in units of volt. | 2 hours |
Dextromethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System

Study Overview
=================
Brief Summary
-----------------
This study is designed to determine whether dextromethorphan, a drug commonly found in cough medicine, is beneficial and safe for the treatment of Parkinson's disease and other diseases that might share biochemical abnormalities with Parkinson's disease. Patients with Parkinson's disease are missing the chemical neurotransmitter dopamine. This occurs as a result of destructive changes in an area of the brain responsible for making dopamine, the basal ganglia. Rhythmical muscular tremors, rigidity of movement, shuffling footsteps, droopy posture, and a mask-like expression on the face characterize Parkinson's disease. Researchers believe that dextromethorphan may be able to safely modify psychomotor function of patients with Parkinson's Disease.

Detailed Description
-----------------
The ability of the putative excitatory amino acid receptor antagonist, dextromethorphan, to modify psychomotor function safely in patients with neurodegenerative disease will be evaluated using a modified double-blind placebo-controlled design. Therapeutic activity will be rated at various doses by means of standard motor and cognitive performance scales. Safety will be assessed at frequent intervals by clinical observation and laboratory tests.

Official Title
-----------------
NMDA Receptor Antagonist Treatment of Neurodegenerative Disease

Conditions
-----------------
Neurodegenerative Disease, Parkinson's Disease

Intervention / Treatment
-----------------
* Drug: dextromethorphan


Participation Criteria
=================
Eligibility Criteria
-----------------
Parkinson's disease or other neurodegenerative disorders in which excessive stimulation of central glutamatergic pathways is hypothesized. Patients must be in good general health and have no history or clinical evidence of significant cardiac (including dysrhythmias), pulmonary, gastrointestinal, renal, hepatic, endocrine, hematological or psychiatric disease. Patient must not evidence any disorder which in the opinion of the investigator imposes an unnecessary risk to the patient or compromises the scientific interpretation of the data. Individuals of child bearing potential must practice appropriate methods of birth control.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: dextromethorphan|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dextromethorphan, Dextrorphan, Glutamate Antagonist, Parkinson's Disease
Modeling of Regional Citrate Anticoagulation With a Dialysate Containing Calcium in Intermittent Hemodialysis (MARC)

Study Overview
=================
Brief Summary
-----------------
The primary purpose of this study is to validate a mathematical modeling of treatment by intermittent hemodialysis using regional citrate anticoagulation with a dialysate containing calcium

Detailed Description
-----------------
The only visit to the study will be carried out during a usual dialysis session in the intensive care unit of Clermont-Ferrand University Hospital. In addition to the usual care, 2 blood samples will be taken from the blood circuit 1 hour after the start of the hemodialysis session by the nurse in charge of the patient.

Official Title
-----------------
Modeling of Regional Citrate Anticoagulation With a Dialysate Containing Calcium in Intermittent Hemodialysis

Conditions
-----------------
End Stage Renal Disease

Intervention / Treatment
-----------------
* Other: blood sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Major patient; Man or woman ; Treated with intermittent hemodialysis for chronic renal failure; In whom intermittent hemodialysis with citrate solution for regional anticoagulation is indicated; Affiliated with a social security scheme; Having given a signed agreement after detailed explanation of the protocol on the basis of the information sheet and likely to comply with it Exclusion Criteria: Severe hepato-cellular insufficiency (PT <50%, INR> 1.5 without anticoagulant); Hemoglobin level <7 g / dL Presenting a psychiatric pathology or cognitive impairment rendering him unable to give informed consent; Persons under guardianship, curatorship, deprived of liberty or safeguard of justice Pregnant or breastfeeding women Patient's refusal to participate in the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients with hemodialysis<br>patient treated with intermittent hemodialysis for chronic renal failure | Other: blood sampling<br>* 2 blood samples will be taken from the blood circuit 1 hour after the start of the hemodialysis session by the nurse in charge of the patient.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ionized calcium level | measured at dialyzer inlet, in mmol/L | day 0 | 
| Total calcium level | measured at dialyzer inlet, in mmol/L | day 0 | 
| Total citratemia | measured at dialyzer inlet, in mmol/L | day 0 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hemodialysis, modeling, Citrate anticoagulation
The Cognitive and Cardiovascular Health in the Elderly Study

Study Overview
=================
Brief Summary
-----------------
The main objective of this study is to look for the interest forecast of the IPS as infra-clinical cardiovascular marker in the prediction of a change of the cognitive functions (MCI) at the elderly of 70 and more years old without clinical cardiovascular pathology.

Official Title
-----------------
The Cognitive and Cardiovascular Health in the Elderly Study

Conditions
-----------------
Cognitive Diseases

Intervention / Treatment
-----------------
* Other: Cardiovascular evaluation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: free-living community-dwelling men and women aged ≥ 70 years, subjects free of clinical CVD related to atherosclerosis preserved basic activities of daily living (ADL = 6) without cognitive impairment (MMSE≥24) Exclusion Criteria: subjects with clinical history of any of the following CVD diseases : coronary artery disease (angina, myocardial infarction, coronary revascularization), cerebrovascular disease (stroke, TIA, carotid revascularization), clinical peripheral artery disease (claudication, critical limb ischemia) subjects with neurodegenerative, locomotor and ophtalmological diseases unable to perform the cognitive tests subjects unable to give written informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Cardiovascular evaluation<br>Measure of the index of systolic pressure Echo doppler Echography Measure of the speed of the wave of pulse and the central pressure | Other: Cardiovascular evaluation<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incident MCI according to the following criteria | (1) cognitive complaint (self-reported and/or informant) ; (2) preserved basic activities of daily living (ADL) ; (3) cognitive impairment (not normal for age and education) or decline in cognition evidenced by performance on objective cognitive tasks defined as a test performance <1.0 standard deviations below the mean of the reference group ; (4) preserved general cognitive functioning and (5) absence of dementia. | one time point | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Alzheimer, cognitive diseases, Ankle-to-brachial index